Please use this identifier to cite or link to this item: https://doi.org/10.1016/S0041-0101(97)00098-6
DC FieldValue
dc.titleA novel antitumour compound from the mucus of a coral, galaxea fascicularis, inhibits topoisomerase I and II
dc.contributor.authorFung, F.M.Y.
dc.contributor.authorDing, J.L.
dc.date.accessioned2014-10-27T08:20:00Z
dc.date.available2014-10-27T08:20:00Z
dc.date.issued1998-07
dc.identifier.citationFung, F.M.Y., Ding, J.L. (1998-07). A novel antitumour compound from the mucus of a coral, galaxea fascicularis, inhibits topoisomerase I and II. Toxicon 36 (7) : 1053-1058. ScholarBank@NUS Repository. https://doi.org/10.1016/S0041-0101(97)00098-6
dc.identifier.issn00410101
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/99917
dc.description.abstractS2 isolated from the mucus of G. fascicularis contains anti- topoisomerase activity, causing cytotoxicity to a multiple-drug resistant leukaemia cell line, P388/VCR. It inhibits DNA relaxation catalysed by topoisomerase I and II. S2 stabilised the topoisomerase I-DNA cleavable complex, thereby inhibiting the DNA replication machinery, leading to cell death. The active centre of S2 probably contains a Galβ(1-4)GlcNAc dissacharide linkage. S2 has potentials of being developed into a new anticancer therapeutic.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/S0041-0101(97)00098-6
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentBIOLOGICAL SCIENCES
dc.description.doi10.1016/S0041-0101(97)00098-6
dc.description.sourcetitleToxicon
dc.description.volume36
dc.description.issue7
dc.description.page1053-1058
dc.description.codenTOXIA
dc.identifier.isiut000074652700010
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Oct 8, 2019

WEB OF SCIENCETM
Citations

7
checked on Oct 8, 2019

Page view(s)

23
checked on Oct 12, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.